Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG

2006750 citationsJournal Articlebronze Open Access

Authors

Jacobus Pfisterer · Kiel University

Marie Plante

Abstract

Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.

Topics & Keywords

Ovarian cancer diagnosis and treatment Intraperitoneal and Appendiceal Malignancies Lung Cancer Research Studies

Publication Details

Published in: Journal of Clinical Oncology

Volume 24, Issue 29, pp. 4699-4707

DOI: 10.1200/jco.2006.06.0913

Field-Weighted Citation Impact: 47.56

Command Palette

Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG

Authors

Abstract

Topics & Keywords

Publication Details